Bhageria Industries Limited has informed the Exchange regarding Board meeting held on May 17, 2025.
BHAGERIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bhageria Industries' board approved audited standalone and consolidated financial results for Q4 and full year ended March 31, 2025, with auditors issuing an unmodified opinion. Standalone revenue from operations grew about 21% YoY to Rs. 59,715.90 lakhs, while net profit more than doubled to Rs. 4,226.54 lakhs (PAT growth of ~115%) versus Rs. 1,962.40 lakhs last year; EPS rose to Rs. 9.68 from Rs. 4.50. The Chemical segment remains the main growth engine, while the Pharma segment continues to report losses. The board also recommended a 30% dividend (Rs. 1.50 per share on Rs. 5 face value), subject to shareholder approval, and appointed new Secretarial, Internal, and Cost Auditors for FY26 onwards.
Strong YoY profit growth driven by the Chemical segment and improved margins should be viewed positively by shareholders, while the dividend recommendation signals steady cash returns. Q4 numbers reflect a sharp earnings jump that may support short-term sentiment, though watch the ongoing losses in the Pharma segment.